113 results about "Interleukin-1beta" patented technology

This invention relates to a method for the biochemical treatment of persistent pain disorders by inhibiting the biochemical mediators of inflammation in a subject comprising administering to said subject any one of several combinations of components that are inhibitors of biochemical mediators of inflammation. Said process for biochemical treatment of persistent pain disorders is based on Sota Omoigui's Law, which states: ‘The origin of all pain is inflammation and the inflammatory response’. Sota Omoigui's Law of Pain unifies all pain syndromes as sharing a common origin of inflammation and the inflammatory response. The various biochemical mediators of inflammation are present in differing amounts in all pain syndromes and are responsible for the pain experience. Classification and treatment of pain syndromes should depend on the complex inflammatory profile. A variety of mediators are generated by tissue injury and inflammation. These include substances produced by damaged tissue, substances of vascular origin as well as substances released by nerve fibers themselves, sympathetic fibers and various immune cells. Biochemical mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.

A method and apparatus for preventing and treating septicemia in patient blood. The extracorporeal system includes an anti-microbial device to kill at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 90% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms as well as the patient's cells and include endotoxins from gram negative bacteria, exotoxins from gram negative and gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, complement proteins C3a and C5a, and brandykinin.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

The invention provides methods and reagents for detecting a polymorphism associated with in an upstream region of the interleukin-1 beta (IL-B) gene (IL-1B (-3737)) that affects transcription of the gene and susceptibility to inflammatory and infectious diseases such as periodontal disease and Alzheimer's disease.

Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I):where A is hydroxy, (C1-C4)alkoxy, amino, hydroxy-amino, mono-(C1-C2)alkylamino, di-(C1-C2)alkylamino; X and Y are independently H or (C1-C2)alkyl; and n is 1 or 2; R6 is halogen, (C1-C3)alkyl, trifluoromethyl, or nitro; R9 is H; (C1-C2)alkyl; phenyl or phenyl-(C1-C2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C1-C2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R', where R1 is (C1-C2)alkyl.This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1beta); increased tumor necrosis factor alpha (TNFalpha); increased ratio of IL-1beta to IL-1 receptor antagonist protein (IRAP); increased expression of p55 TNF receptors (p55 TNF-R); increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGFbeta); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP); increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge; increased urokinase plasminogen activator (uPA); increased cartilage oligomeric matrix protein; and increased collagenase.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

The invention discloses application of an exosome coming from umbilical cord mesenchymal stem cells optimized with interleukin-1beta (IL-1beta) in treating sepsis. Specifically, recombined IL-1beta of human is used for optimizing the umbilical cord mesenchymal stem cells to enhance the immunosupression function of the umbilical cord mesenchymal stem cells, and the exosome generated by the umbilical cord mesenchymal stem cells is extracted and used for treating sepsis. The exosome can effectively relieve the symptoms of sepsis, and increase the survival rate of mice suffering from sepsis; besides, the exosome has the advantages of being convenient to preserve and transport, and thus a new strategy is provided for treating diseases related to refractory inflammation such as sepsis.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

A method for treating renal disease includes administering to a patient suffering from renal disease an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can be employed. Antibody, functional equivalent thereof or soluble cytokine receptor to interleukin 10 or interleukin 13 also can be administered. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof; and, optionally, antibody, functional equivalent or soluble cytokine receptor to interleukin 10, interleukin 13 or both. The composition can be included in a kit.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

The invention relates to a grass carp interleukin 1 beta gene and protein and a recombinant expression method thereof. The invention provides the grass carp interleukin 1 beta gene and the grass carp interleukin 1 beta protein coded by the gene. The recombinant expression method of the invention adopts homology cloning technology to clone and obtain the cDNA complete sequence of the grass carp interleukin 1 beta gene, uses the mature peptide sequence of the grass carp interleukin 1 beta gene to construct a prokaryotic expression vector and screens out a recombinant expression system used for efficiently expressing the grass carp interleukin 1 beta gene. The recombinant expression method of the invention comprises the following steps: 1. performing gene cloning; 2. constructing and screening the recombinant expression vector; and 3. expressing the recombinant protein, and separating and purifying the expression products. The beneficial effect of the invention is that the technical scheme of the invention can be used to perform the industrialized production of the recombinant interleukin 1 beta, and the recombinant interleukin 1 beta can be used in the theoretical research of the immunologic mechanism of fish.

Methods and compositions for inhibiting 5-Lipoxygenase, 15-Lipoxygenase, COX-1, COX-2, Interleukin-lβ, Interleukin-6, α, HLE, and iNOS. Methods and compositions for treating and preventing diseases, including inflammatory diseases and skin cancer. Compositions comprising processed Morinda citrifolia components, some of which include leaf extracts, leaf juice, and / or seed extracts.

The invention relates to the technical field of biology, in particular to application of plants as hosts in expressing canakinumab. Plants such as lettuce are adopted as an effective expression platform of recombinant protein production, and a simple and effective agrobacterium tumefaciens mediated transformation vacuum infiltration method is utilized to express canakinumab, ilaris, ACZ885, anti-human IL-1beta-monocolonal antibody. The expression system can be collected after it is determined that botanical foreign protein is infected with agrobacterium for 4 d. An SDS-PAGE method is utilizedto determine that the recombinant canakinumab is successfully expressed. As is proved by polymorphonuclear leukocyte inhibition experiments, the canakinumab produced by the lettuce has biological activities of inhibiting interleukin-1beta and inhibiting neutrophile granulocyte.

The invention sets up an anti-inflammatory drug screening primary culture cell model which takes interleukin 1 beta gene of human beings as a target and is high-efficient and reliable, and a screening method thereof. The invention separates and primarily cultures a abdominal cavity macrophagus of the transgenic mouse which is introduced with interleukin 1 beta promoter drive of human beings and expressed by luciferase reporter gene, so that a macrophagus inflammatory model is set up by the inducement of inflammation motivating factor. In the model, the anti-inflammatory activity of the compound can be evaluated by measuring the degree of inhibiting the expression of the reporter gene of the screened compound. The drug screening model set up by the invention is a cell model which is sensitive, high-efficient, reliable and suitable for screening high flux anti-inflammatory drug.

The invention belongs to the biotechnology field and discloses a ctenopharyngodon idellus interleukin-1beta (IL-1beta) competitive inhibiting enzyme-linked immunosorbent assay (ELISA) kit. The kit comprises the following components: (1) an ELISA plate, (2) a horse radish peroxidase marked ctenopharyngodon idellus IL-1beta polyclonal antibody concentrated solution, (3) a sample diluent, (4) washing concentrate, (5) concentrated coating buffer, (6) a chromogenic substrate, (7) stop buffer and (8) standard ctenopharyngodon idellus IL-1beta. The kit has the characteristics of simplicity in operation, good repeatability, accuracy and specificity and wide linear detection range.

Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1β post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human α-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human α-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-1β.

The invention discloses a compound probiotic preparation. The compound probiotic preparation is characterized by being composed of bacillus licheniformis, saccharomyces cerevisiae, bifidobacterium animalis, lactobacillus acidophilus, streptococcus thermophilus, tryptophan, xylo-oligosaccharides, galactomannan and zinc lactate. The compound probiotic preparation disclosed by the invention is capable of effectively improving growth conditions of piglets so as to increase daily weight gain and reduce diarrhea rate; moreover, the compound probiotic preparation is also capable of increasing levelsof interleukin-1-beta (IL-1-beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and intestinal mucosa SIgA in the piglet body so as to enhance disease resistance of the piglets, as well as helping the piglets to establish healthy intestinal flora environment. In addition, the compound probiotic preparation is low in production cost as well as easy to promote and use, and has wideapplication prospects.

The invention belongs to the field of biomedicine, and relates to a fusion protein for sub-cellular localization and an application thereof. A system can be used for reporting the activity of inflammasomes on the organelle level mainly based on secretion type luciferase. 7 kinds of plasmids included in the system are mainly obtained by sequentially cloning an organelle localization gene, an interleukin 1beta precursor coding gene (pro-IL-1beta) and secretion type luciferase (DN-Gluc) to a multiple cloning site zone of an expression vector pcDNA3.1. The plasmids included in the system are transfected to target cells respectively, and the activity of the inflammasomes can be quantitatively analyzed by detecting the activity of luciferase in extracellular supernate, so that the system has the advantages of high efficiency, fastness, simplicity, convenience and the like and can be applied to medicament screening, molecular mechanisms, live animal research and development of related products related to the inflammasomes.

Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof. The formulations may include an inhibitor such as an inhibitor of tumour necrosis factor alpha (TNFa), platelet-derived growth factor subunit A (PDGFA), platelet-derived growth factor subunit B (PDGFB), platelet-derived growth factor subunit C (PDGFC), platelet-derived growth factor subunit D (PDGFD), platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), platelet-derived growth factor receptor like (PDGFRL), vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC) vascular endothelial growth factor D (VEGFD), vascular endothelial growth factor receptor-1 (VEGFR1), vascular endothelial growth factor receptor-2 (VEGFR2), vascular endothelial growth factor receptor-3 (VEGFR3), beta-2 adrenergic receptor (ADRB2), connective tissue growth factor (CTGF), interleukin 1 beta (IL1 β), interleukin 1 receptor-1 (IL1 R1), interleukin 1 receptor-2 (IL1R2), and interleukin 1 receptor-3 (IL1R3). Aspects of the invention further relate to nanostructures comprising self-assembling therapeutic oligonucleotides, such as antisense oligonucleotides, that are linked to a molecular species, wherein the molecular species is positioned in a core of the nanostructure and the oligonucleotides extend radially from the core.

The invention discloses a breeding method of a new disease-resistance large white pig strain. The method includes the following steps that 1, a feed adding method is adopted to conduct an Escherichia coli infection experiment on weaned piglets of a core group in large white pigs, and an Escherichia coli resistant breeding basic group in the large white pigs is established; 2, concentration determination is conducted on cytokines of interleukin 1beta, interleukin 4, interleukin 6, interleukin 8, interleukin 10, transforming growth factor beta, tumor necrosis factor alpha and interferon gamma of an Escherichia coli resistant population in the basic group; reproductive performances are detected and selected, growth speeds, lean meat ratios and carcass quality characters, and a first generation is established; 3, a group subculture selective breeding method and a molecular-marker-assisted selection method are adopted. In this way, by the adoption of the breeding method of the new disease-resistance large white pig strain, after four to five generations, a vested breeding target is achieved gradually, a new-strain core group is established, and the morbidity of piglet diarrheal diseases is expected to be reduced.

The invention relates to a method for simultaneously detecting 17 genes. Sequences of mRNA of interleukin-1beta (IL-1beta, NM-000576, etc.) and sapiens glycerol kinase (NM-203391) are referred to on PUBMED; a reverse transcription primer and a PCR primer are designed; reverse transcription, PCR amplification and capillary electrophoresis are performed; and quantitative analysis is performed by a Gexp analysis system. The detection method not only comprises a quality control gene of a kanamycin resistance gene (Kan, R) for monitoring the reaction system, but also designs two amplified products for L-selectin which are used to detect the stability of the reaction system. The invention has the advantages of small sample size required, high sensitivity and accuracy. The method analyzes the properties and components of an atherosclerotic plaque by detecting the expression situation of peripheral blood related genes, and establishes a technical platform for batch screening of differential genes between cardiovascular diseases and controls.

A homogeneous interleukin 1 beta (IL-1 beta ), its derivative having a modified amino acid sequence of IL-1 beta , a gene coding for said derivative, medical composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1 beta and the derivative.

The invention discloses an application of novel eye drops in treatment of dry eyes. The novel eye drops contain alpha-MSH; the mass concentration of the alpha-MSH is 10<-4> to 10<-3>mg / ml; the novel eye drops are used for treating the dye eyes; and the optimized mass concentration of the alpha-MSH is 10<-4>mg / ml. By using the novel eye drops, experiment analysis on the breakup time of a tear film (BUT), schirmer test, fluorescein staining, grade and tear ferns is carried out on rats; an overall eyeball of each rat is extracted to be subjected to HE and periodic acid-Schiff (PAS) staining; and the fresh cornea of each rat is extracted to be subjected to real-time quantitative PCR detection of expression levels of interleukin-1beta and tumor necrosis factor-alpha m RNA in corneal tissues, so that the experiments prove that the eye drops containing alpha-MSH are capable of promoting schirmer in rats, prolonging the breakup time of the tear film, stabilizing the tear film, promoting corneal epithelium damage repair and goblet cell quantity repair, and relieving ocular surface inflammation, and are favorable for relieving lesions of the dry eyes.